Intercept Pharma (ICPT) Tops Q2 EPS by 26c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
Go back to Intercept Pharma (ICPT) Tops Q2 EPS by 26c, Revenues Beat
August 6, 2018 7:47 AM EDT
Wedbush raised its price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $217.00 (from $203.00) while maintaining a Outperform rating.
...
More
August 6, 2018 5:12 AM EDT
(Updated - August 6, 2018 7:41 AM EDT)
(updated to correct prior recommendation)
Goldman Sachs upgraded Intercept Pharmaceuticals (NASDAQ: ICPT) from Sell to Buy with a price target of $157.00 (from $46.00).
Analyst Salveen Richter says the company's Ocaliva in NASH is the most improtant... More
August 3, 2018 7:42 AM EDT
Cantor Fitzgerald raised its price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $69.00 (from $58.00) while maintaining a Neutral rating following the company's 2Q earnings report. For the quarter, ICPT reported net Ocaliva revenues of $43.2 million, slightly above estimates of $42.0 million.
Despite the... More
August 3, 2018 7:15 AM EDT
Cowen raised its price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $120.00 (from $88.00) while maintaining a Outperform rating.
Analyst Ritu Baral commented, "ICPT 2Q earnings beat revenue expectations: the Ocaliva launch is showing early signs of stabilization and renewed growth. Next... More
August 2, 2018 12:55 PM EDT
RBC Capital lowered its price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $115.00 (from $116.00) while maintaining an Outperform rating.
Analyst Brian Abrahams notes Ocaliva PBC revenues slightly beat expectations, with strengthening U.S. and ex-U.S. uptake following the label update. He said... More
